Loading...
XMADFAE
Market cap1.10bUSD
Dec 20, Last price  
3.40EUR
1D
-0.87%
1Q
-8.36%
Jan 2017
1.19%
Name

Faes Farma SA

Chart & Performance

D1W1MN
XMAD:FAE chart
P/E
11.51
P/S
2.35
EPS
0.30
Div Yield, %
1.38%
Shrs. gr., 5y
2.38%
Rev. gr., 5y
6.83%
Revenues
451m
+2.83%
163,009,000166,449,000185,187,000185,940,000194,180,000131,406,000202,507,000190,224,000176,109,000180,394,000191,742,000204,724,000228,635,000274,576,000324,312,000357,398,000380,240,000398,557,000438,754,000451,168,000
Net income
92m
+2.69%
23,793,00023,273,00022,772,00022,149,00019,615,00018,161,00020,002,00014,181,00019,518,00022,605,00025,334,00030,361,00036,591,00042,221,00051,592,00063,962,00072,549,00082,390,00089,496,00091,902,000
CFO
101m
-5.45%
19,930,00013,044,00034,308,00016,946,00015,238,00019,975,00023,872,00031,647,00032,259,00040,912,00049,625,00041,727,00059,336,00067,585,00078,489,00079,645,000106,788,000100,969,000
Dividend
Jul 04, 20240.116 EUR/sh
Earnings
Feb 25, 2025

Profile

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
URL
https://faesfarma.com/
IPO date
Mar 25, 1994
Employees
1,764
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
451,168
2.83%
438,754
10.09%
398,557
4.82%
Cost of revenue
216,621
212,926
199,363
Unusual Expense (Income)
NOPBT
234,547
225,828
199,194
NOPBT Margin
51.99%
51.47%
49.98%
Operating Taxes
11,159
11,919
10,775
Tax Rate
4.76%
5.28%
5.41%
NOPAT
223,388
213,909
188,419
Net income
91,902
2.69%
89,496
8.62%
82,390
13.56%
Dividends
(14,607)
(18,147)
(13,719)
Dividend yield
1.49%
1.69%
1.29%
Proceeds from repurchase of equity
(17,686)
BB yield
1.80%
Debt
Debt current
19,523
28,285
14,283
Long-term debt
10,979
10,565
6,406
Deferred revenue
4,786
157
Other long-term liabilities
4,570
35
4,442
Net debt
(4,481)
(50,382)
(50,555)
Cash flow
Cash from operating activities
100,969
106,788
79,645
CAPEX
(102,190)
(80,948)
(59,417)
Cash from investing activities
(97,356)
(92,172)
(83,485)
Cash from financing activities
(35,377)
(18,459)
(17,116)
FCF
144,848
140,788
108,422
Balance
Cash
47,751
84,100
73,408
Long term investments
(12,768)
5,132
(2,164)
Excess cash
12,425
67,294
51,316
Stockholders' equity
673,561
617,405
541,919
Invested Capital
679,390
570,184
506,139
ROIC
35.75%
39.75%
40.96%
ROCE
33.09%
34.36%
34.64%
EV
Common stock shares outstanding
310,729
305,920
304,825
Price
3.16
-9.97%
3.51
0.92%
3.48
-0.34%
Market cap
981,905
-8.56%
1,073,779
1.28%
1,060,180
4.02%
EV
978,418
1,024,600
1,011,163
EBITDA
253,945
245,099
215,429
EV/EBITDA
3.85
4.18
4.69
Interest
684
263
216
Interest/NOPBT
0.29%
0.12%
0.11%